the High Authority of Health advises against the use of the Moderna vaccine for those under 30 years old because of an increased risk of myocarditis in the youngest

HAS plays the card of caution. The High Authority for Health recommended, Monday, November 8, to favor the use of the Pfizer-BioNTech vaccine for those under 30, because of higher cardiac risks with Moderna’s vaccine. THEThe risk of very rare cases of myocarditis “appears about five times less for Pfizer’s Comirnaty vaccine compared to Moderna’s Spikevax vaccine (100 µg) in 12-29 year olds”, justifies the authority, on the basis of a vast French study on the subject.

In its opinion, the HAS also gives the green light to the resumption of booster doses for over 30s with the Moderna vaccine. These injections were suspended in mid-October, notably for lack of an extension of the marketing authorization in Europe. Such approval has since been registered for the additional doses for adults. The effectiveness of this vaccine “looks slightly better” than that of Pfizer-BioNTech, underlines the HAS.

Moderna and Pfizer vaccines are “safe and effective” corn “Studies show a slight superiority of Spikevax in terms of efficacy and lower risks of myocarditis for Comirnaty, especially for people under 30 years old”, summarizes the HAS.